Trends in Drug Discovery & Development: March 2019
Expert interviews on a novel target for glioblastoma, new approach to Alzheimer’s disease therapy, mapping tumors at the molecular level and more
Expert interviews on a novel target for glioblastoma, new approach to Alzheimer’s disease therapy, mapping tumors at the molecular level and more
Just as color transformed black and white movies, so ColorSEM Technology has smashed the boundaries of microscopy, allowing researchers to visualize hidden wonders in color
Amniocyte Derived Human Cell Line CAP-T® is a Versatile Host for Transient Bulk Transfection
The Agilent Microplate Labeler fits easily on a benchtop, while its speed allows users to achieve their aggressive throughput goals.
Single Molecular Imaging with up to 6 Laser Lines.
Immunodensity negative selection cocktail
Immunodensity negative selection cocktail
The Invitrogen™ PowerEase™ Touch 350W Power Supply brings a new level of convenience to your electrophoresis experiments. With a bright LCD touchscreen interface, you can enter in custom programs or use the preprogrammed protocols for Invitrogen™ protein gels and gel transfers. It can run up to 8 midi gels or transfer up to 4 midi gels simultaneously.
The OMNIS NIR Analyzer extends the modular OMNIS platform beyond wet chemistry techniques to also include near-infrared spectroscopy. With the OMNIS NIR Analyzer anyone can measure liquid, viscous, and solid samples in less than 10 seconds at the touch of a button.
Explore the latest developments in clinical laboratory science, from new diagnostic approaches to cutting-edge point-of-care technologies, improving patient care, and more
An automated next-generation sequencing library preparation workstation
As we celebrate the first regulatory approval of a gene-editing based therapeutic, Casgevy™, for the treatment of sickle cell disease and transfusion-dependent β-thalassemia, we consider the gene-editing challenges that must be overcome before CRISPR gene-editing technology becomes a common treatment modality